ScreenerHero

PHAR Pharming Group N.V.

NAS · US · Healthcare · Biotechnology · pharming.com
9.650USD-0.31%Mkt Cap: 683.01M $P/E: 74.23

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. Th…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap683.01M USD
Enterprise Value640.15M USD
Revenue (TTM)366.48M USD
Gross Profit330.63M USD
Net Income (TTM)2.85M USD
Revenue/Share5.22 USD
Last Price9.650 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees407
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)74.23
P/E (Forward)31.53
PEG—
EV/EBITDA19.47
EV/Revenue1.75
P/S1.87
P/B2.53
EPS (TTM)0.13
EPS (Forward)0.31
52W Range
9.5901% of range21.34
52W High21.34 USD
52W Low9.590 USD
Profitability
Gross Margin87.90%
Oper. Margin1.46%
EBITDA Margin8.97%
Profit Margin0.76%
ROE1.03%
ROA0.57%
Growth
Revenue Growth-3.20%
Earnings Growth-62.90%
Cash Flow & Leverage
Operating CF54.71M USD
CapEx (TTM)755.00K USD
FCF Margin10.28%
FCF Yield5.52%
Net Debt-44.99M USD
Net Debt/EBITDA-1.37
Balance Sheet
Debt/Equity0.42
Current Ratio3.01
Quick Ratio2.31
Book Value/Sh3.82 USD
Cash/Share2.24 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)34.35 USD
Upside (mean)+256.0%
Target Range23.40 USD – 39.00 USD
23.40+256.0% to mean39.00
# Analysts4
Ownership
Shares Out.70.78M
Float69.66M
Insiders0.00%
Institutions0.14%
Short Interest
Short Ratio1.2d
Short % Float0.03%
Short % Out.0.03%
Shares Short20.88K
Short (prev mo.)72.69K
Technical
SMA 5011.13 (-13.3%)
SMA 20014.46 (-33.2%)
Beta0.07
S&P 52W Chg15.78%
Avg Vol (30d)23.23K
Avg Vol (10d)32.93K
Technical Indicators
RSI (14)33.8
MACD-0.4854
MACD Signal-0.4252
MACD Hist.-0.0603
BB Upper11.65 USD
BB Middle10.50 USD
BB Lower9.338 USD
BB Width22.06%
ATR (14)0.4336 USD
Vol Ratio (20d)0.15x